ABSTRACT
The implications of advanced glycation end products (AGEs) and advanced lipoxidation end products (ALEs) on the pathogenesis of diabetes-mediated uremic complications as well as on aging and atherosclerosis have been recognized for some time. In addition, the roles of reactive carbonyl compounds and of reactive oxygen species (ROS) in pathologies related to diabetes, atherosclerosis, Alzheimer’s disease, as well as the aging process have received much consideration. Any chemical that would have inhibitory action on any of these individual steps leading to pathologies affecting the micro-and macrovascular systems would have therapeutic potential. Many such chemicals have been identied of which pyridoxamine, a vitamin B6 vitamer, and benfotiamine, a lipid-soluble form of thiamine (vitamin B1), have a very signicant place in the therapy of micro-and macrovascular defects associated with many chronic diseases.
